Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Autolus Therapeutics logo — Focused on the development of precisely targeted, controlled...

Autolus Therapeutics

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer

Founded 2014 United Kingdom London, United Kingdom 763 employees Post Ipo Equity Total: $1.07B Biopharma, Biotechnology +1

General Information

Company Name Autolus Therapeutics
Founded Year 2014
Location United Kingdom London, United Kingdom +2
Founders / Decision Makers
Team member
Employees 763
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Autolus Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Autolus Therapeutics

Autolus Therapeutics, founded in 2014, is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries. Based in the United Kingdom, the company is renowned for its innovative approach towards cancer treatment, with a clear focus on developing precisely targeted and highly controlled T cell therapies.

The company's technology centers on advanced autologous CAR T cell therapies, which leverage comprehensive programming capabilities to potentially deliver life-altering treatments for patients with cancer and autoimmune diseases. This approach aligns with their slogan, which emphasizes precision and activity in targeting cancer cells.

In their recent financial move, Autolus Therapeutics secured a substantial investment of $350.00M through a Post-IPO Equity, as of February 8, 2024. This substantial capital injection evidences strong investor confidence and provides the company with resources to advance its therapeutic developments and uphold its growth trajectory.

Taxonomy: CAR T cell therapy, T cell programming, Cancer treatment, Autologous T cell therapies, Next-generation therapies, Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, AUTO8, Autoimmune disease treatment, Biopharmaceuticals, Therapeutic pipeline

Services & Products

Development of autologous T cell therapies
Advanced cell programming
Manufacturing of T cells
Clinical trial management
Pipeline products for cancer and autoimmune diseases

Target Customers

Patients with cancer and autoimmune diseases Healthcare professionals Investors interested in biotech innovations Research institutions

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 08 Feb 2024
Post-IPO Equity •••••• - 08 Dec 2022
Post-IPO Equity •••••• 1
Investor
08 Nov 2021
Post-IPO Equity •••••• - 10 Feb 2021
Post-IPO Equity •••••• 1
Investor
17 Sep 2019

View All 10 Funding Rounds

Autolus Therapeutics Alternatives & Competitors

View All Alternatives
Autolus Therapeutics vs
Medigene AG
Medigene AG

Next Generation TCRs for Precision Immunotherapies

Autolus Therapeutics vs
Laverock Therapeutics
Laverock Therapeutics United Kingdom

Programmable advanced therapies

Seed
35 employees
Biotechnology, Health and Wellness
Compare Autolus Therapeutics vs Laverock Therapeutics
Autolus Therapeutics vs
MY GENE AND CELL THERAPIES
MY GENE AND CELL THERAPIES Turkey

Pioneering synthetic biology to engineer CAR‑T cells for immunotherapy.

2 employees
Also compare with: Autolus Therapeutics vs DAAN Biotherapeutics DAAN Biotherapeutics Autolus Therapeutics vs Xap Therapeutics Xap Therapeutics Autolus Therapeutics vs 2seventy bio 2seventy bio View all alternatives

FAQ About Autolus Therapeutics

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer
Autolus Therapeutics was founded in 2014.
Autolus Therapeutics is headquartered in London, United Kingdom.
Autolus Therapeutics operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Autolus Therapeutics has approximately 763 employees.
Autolus Therapeutics has completed 10 funding rounds, raising a total of $1.07B. The latest funding stage is Post Ipo Equity.
Autolus Therapeutics offers: Development of autologous T cell therapies, Advanced cell programming, Manufacturing of T cells, Clinical trial management, Pipeline products for cancer and autoimmune diseases.
Top alternatives and competitors to Autolus Therapeutics include Medigene AG, Laverock Therapeutics, MY GENE AND CELL THERAPIES, DAAN Biotherapeutics, Xap Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Autolus Therapeutics and Medigene AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Autolus Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy